All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

aminopterin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
folic acid analogues	21	54-62-6

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: 4-aminofolic acid Aminofolic acid, 4- aminopterin aminopterine pteramina aminopterin sodium

Aminopterin is a folic acid amino derivative with antineoplastic and immunosuppressive properties. It binds competitively to the folate binding site of the enzyme dihydrofolate reductase, blocking tetrahydrofolate synthesis, and resulting in depletion of nucleotide precursors and inhibition of DNA, RNA and protein synthesis. Molecular weight: 440.42 Formula: C19H20N8O5 CLOGP: -0.86 LIPINSKI: 2 HAC: 13 HDO: 6 TPSA: 219.33 ALOGS: -3.62 ROTB: 9

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,GRK3,GSK3B,ITK,JAK1,JAK2,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK12,MAPK7,MARK4,MTOR,NTRK1,NTRK2,PDK1,PDK2,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1	50
kinase-selectivity-class	AXL,BRAF,EIF2AK3,GRK2,GRK3,MAPK7,PIK3CD,TEK,TTK	9
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	0.445		Moderate	0.71
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pld-class	Phospholipidosis risk class (1 = positive, 0 = negative)	0		Moderate	0.71
rat-kpuu-brain	Rat brain Kpuu	0.005	%	Moderate	0.71

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D005493	Folic Acid Antagonists
CHEBI has role	CHEBI:25435	mutagen
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:35842	antirheumatic drug
CHEBI has role	CHEBI:50683	EC 1.5.1.3 (dihydrofolate reductase) inhibitor
CHEBI has role	CHEBI:50748	antipsoriatic

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Leukemia, disease	indication	93143009	DOID:1240

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.61	acidic
pKa2	4.86	acidic
pKa3	12.96	acidic
pKa4	5.46	Basic
pKa5	4.51	Basic
pKa6	2.08	Basic
pKa7	1.39	Basic
pKa8	0.25	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Dihydrofolate reductase	Enzyme	P00374	DYR_HUMAN	INHIBITOR	IC50	4.93		SCIENTIFIC LITERATURE	EXPERT CURATOR
Dihydrofolate reductase	Enzyme		DYR_MOUSE		IC50	8.70		CHEMBL
Dihydrofolate reductase	Enzyme		DYR_ECOLI		IC50	7.96		CHEMBL
Dihydrofolate reductase	Enzyme		DYR_LACCA		IC50	8.30		CHEMBL
Dihydrofolate reductase	Enzyme		B0BL08_ECOLX		IC50	7.96		CHEMBL
Folylpoly-gamma-glutamate synthetase	Enzyme		FOLC_MOUSE		Ki	4.75		CHEMBL

External reference:

ID	Source
N0000007861	NUI
D02527	KEGG_DRUG
1440263	RXNORM
CHEBI:22526	CHEBI
04J	PDB_CHEM_ID
CHEMBL376180	ChEMBL_ID
CHEMBL2104643	ChEMBL_ID
58602-66-7	SECONDARY_CAS_RN
DB08878	DRUGBANK_ID
JYB41CTM2Q	UNII
C0002583	UMLSCUI
D000630	MESH_DESCRIPTOR_UI
169371	PUBCHEM_CID
333	INN_ID
6790004	SNOMEDCT_US
JYB41CTM2Q	INXIGHT DRUGS

Pharmaceutical products:

None